Lytix Biopharma AS (OSL:LYTIX) Accounts Payable: kr4.49 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:LYTIX Lytix Biopharma AS OSL:LYTIX
30 GF Score
Price kr8.50
GF Value kr0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS Accounts Payable?

Lytix Biopharma AS OSL:LYTIX +0.95% 30 Accounts Payable is kr4.49 Mil as of Mar. 2026. GuruFocus rates OSL:LYTIX with a GF Score™ of 30/100 and a GF Value™ of kr0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Lytix Biopharma AS's Accounts Payable for the quarter that ended in Mar. 2026 was kr4.49 Mil.

Lytix Biopharma AS's quarterly Accounts Payable increased from Sep. 2025 (kr4.99 Mil) to Dec. 2025 (kr6.38 Mil) but then declined from Dec. 2025 (kr6.38 Mil) to Mar. 2026 (kr4.49 Mil).

Lytix Biopharma AS's annual Accounts Payable increased from Dec. 2023 (kr3.57 Mil) to Dec. 2024 (kr5.02 Mil) and increased from Dec. 2024 (kr5.02 Mil) to Dec. 2025 (kr6.38 Mil).

Lytix Biopharma AS Accounts Payable Related Terms

Lytix Biopharma AS Accounts Payable Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS Accounts Payable Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 1.48 7.00 3.57 5.02 6.38

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.83 2.72 4.99 6.38 4.49
OSL:LYTIX
30GF Score
Lytix Biopharma AS OSL:LYTIX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of kr4.49 Mil mean?
Lytix Biopharma AS (OSL:LYTIX) has a Accounts Payable of kr4.49 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's Accounts Payable too high?
Lytix Biopharma AS's current Accounts Payable is kr4.49 Mil. Overall, Lytix Biopharma AS has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Accounts Payable compare to VRTX and REGN?
Lytix Biopharma AS's Accounts Payable of kr4.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current Accounts Payable is kr4.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Based on GuruFocus' analysis, Lytix Biopharma AS (OSL:LYTIX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.17, compared to a current price of kr8.50 — trading 4900% above its estimated fair value. The current Accounts Payable is kr4.49 Mil. Lytix Biopharma AS's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Lytix Biopharma AS (OSL:LYTIX), the current Accounts Payable is kr4.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of kr8.50 is trading 4900% above its estimated GF Value™ of kr0.17. GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.

Key valuation signals for OSL:LYTIX:

  • Accounts Payable: kr4.49 Mil
  • GF Value™: kr0.17 vs. price of kr8.50 (4900% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
30GF Score

Get the complete analysis for OSL:LYTIX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.50
Price
kr0.17
GF Value